Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.1B
69M shares
52-week range
$8.73 – $71.50
55% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
153
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
www.uniqure.comNo one on the platform currently holds QURE.
No tracked institution reports a position in QURE as of their last filing.
No one on the platform has traded QURE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -40.6% | -15.6% | ||||
| Profit Margin % | -1236.0% | -824.5% | -780.6% | |||
| Free Cash Flow Margin % | -1105.5% | -571.8% | -629.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $22M | +41.6% | $-3.92 | $-4.24–$-3.64 | — | 8 |
| 2027 | $135M | +505.5% | $-3.05 | $-3.46–$-2.44 | — | 9 |
| 2028 | $409M | +202.1% | $-1.12 | $-4.24–$3.11 | — | 7 |
| 2029 | $653M | +59.7% | $1.20 | $0.07–$2.97 | 36.0× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $-0.82 | $-1.22 | -48.4% |
| 2026-05-05 | $-0.88 | $-0.85 | +3.4% |
| 2026-03-02 | $-0.93 | $-0.56 | +39.8% |
| 2025-11-10 | $-0.85 | $-1.38 | -62.4% |
| 2025-07-29 | $-0.89 | $-0.69 | +22.5% |
| 2025-05-09 | $-1.07 | $-0.82 | +23.4% |
| 2025-02-27 | $-0.60 | $-1.50 | -150.0% |
| 2024-11-05 | $-1.12 |
| $-0.91 |
| +18.8% |
| $1.8B |
| — |
| GPCRStructure Therapeutics Inc. | $38.95 | +1.33% | $2.2B | — |
| MESOMesoblast Limited | $14.74 | -1.86% | $1.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
$QURE $CGON $AVBP might be worth doing cheap lottos on these in case they drop data before 9/18 opex. Not sure if Uniqure will move much though.
View on StockTwits ↗
$QURE Going up today, stop woth the ball tickling and release the press release with the data 😩
View on StockTwits ↗
$QURE 50-72 is what I told you. Data drop before end of September $CLPT lagging wayyyy behind but what do I know
View on StockTwits ↗
@MihalisB86 ,,, I wouldn't go to big on them.... I often hold micro stakes in odd Biotechs.... and then... sunnedly one surprises me $OPUS.X were one, as were $QURE ... and $ANRO maybe also have a bit to rally before readouts...maybe $SVA will be nice one (just announced merger and pushing on with T1D - only 3 other companies in the same space). My lesson is - just cos a biotech sounds interesting - doesn't me I need shares - I can just teach and then kick myself if the POP... LOL
View on StockTwits ↗$QURE bro just release the data 😩 you should have all the data cleaned up for the data lock already what is taking them so long
View on StockTwits ↗
$QURE fuck the control arm if the patients are improving across their cUHDRS score their brains are literally healing from the therapy. $CLPT $XBI
View on StockTwits ↗
$QURE Great Patriot Dr. Sung had this to say earlier: "Bears Beware!" I have reloaded accordingly.
View on StockTwits ↗
$QURE AI says pdufa might fall for April and adcom may fall February or March.
View on StockTwits ↗$QURE Im feeling it in my groins. 4 year data after the close 😩
View on StockTwits ↗
$QURE Why not wait few weeks for the 4 year data and then submit the BLA ? Strange !
View on StockTwits ↗
$QURE if not bouncing from 43 $, uptrend will be broken
View on StockTwits ↗
$QURE Prior FDA leadership were very open about their opinion that the drug has failed in trial, and that the "success" was the result of data manipulation and patient selection. There was no placebo group in trial, so no randomization. On the other hand, conducting mock brain surgery would be difficult to sell to the public. In the end, we are where we are, due to media and political pressure that the company was able to exert, not because of any scientific reconsideration. If the people in charge of FDA considered this drug a failure, it would be stupid to deny even the existance of such a possiblily manifesting itself at one point or another....
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.